论文部分内容阅读
目的探讨瑞舒伐他汀治疗急性冠脉综合征(ACS)合并心律失常的临床疗效及其对患者炎性因子的影响。方法选取湘西自治州人民医院2015年8月—2016年8月收治的ACS合并心律失常患者120例,根据随机数字表法分为对照组和观察组,各60例。患者入院后均给予常规对症治疗,对照组患者给予洛伐他汀治疗,观察组患者给予瑞舒伐他汀治疗,两组患者均持续治疗2周。比较两组患者的临床疗效,治疗前后血脂指标[低密度脂蛋白胆固醇(LDL-C)、总胆固醇、三酰甘油]及炎性因子[超敏C反应蛋白(hs-CRP)、白介素18(IL-18)、肿瘤坏死因子α(TNF-α)],并观察两组患者不良反应发生情况。结果观察组患者治疗总有效率高于对照组(P<0.05)。治疗前及治疗后,两组患者LDL-C、总胆固醇和三酰甘油比较,差异无统计学意义(P>0.05);两组患者治疗后LDL-C、总胆固醇和三酰甘油低于治疗前(P<0.05)。治疗前,两组患者hs-CRP、IL-18、TNF-α水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者hs-CRP、IL-18、TNF-α水平低于对照组(P<0.05)。两组患者均未出现严重不良反应。结论采用瑞舒伐他汀治疗ACS合并心律失常临床疗效确切,可有效抑制患者的炎性反应,且具有一定的调脂作用,安全性好。
Objective To investigate the clinical efficacy of rosuvastatin in the treatment of acute coronary syndrome (ACS) with arrhythmia and its effect on inflammatory factors. Methods 120 patients with ACS complicated with arrhythmia admitted from August 2015 to August 2016 in People’s Hospital of Xiangxi Autonomous Prefecture were divided into control group and observation group according to random number table method, 60 cases in each group. All patients were given conventional symptomatic treatment after admission. Patients in the control group were treated with lovastatin, and patients in the observation group were treated with rosuvastatin. Both groups were treated for 2 weeks. The clinical effects of two groups of patients were compared. The levels of serum lipids, including low-density lipoprotein cholesterol (LDL-C), total cholesterol and triglyceride, and inflammatory cytokines [hs-CRP, IL-18) and tumor necrosis factor-α (TNF-α), and the occurrence of adverse reactions in both groups were observed. Results The total effective rate of observation group was higher than that of control group (P <0.05). There was no significant difference in LDL-C, total cholesterol and triglyceride between the two groups before and after treatment (P> 0.05). LDL-C, total cholesterol and triglyceride were lower in both groups after treatment Before (P <0.05). Before treatment, the levels of hs-CRP, IL-18 and TNF-αin the two groups had no significant difference (P> 0.05). After treatment, the levels of hs-CRP, IL-18 and TNF- In the control group (P <0.05). No serious adverse reactions occurred in both groups. Conclusions The clinical efficacy of rosuvastatin in the treatment of ACS complicated with arrhythmia is exact, which can effectively inhibit the inflammatory reaction in patients with certain lipid-lowering effects and has good safety.